In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sirna, Allergan enter multi-year deal for ophthalmic drugs

Executive Summary

In its largest deal to date, Sirna Therapeutics (develops RNAi-based therapies) has signed a multi-year agreement with Allergan to develop Sirna027, its modified short-interfering RNA (siRNA) drug candidate for age-related macular degeneration (AMD). The companies will also discover and develop other RNAi-based therapeutics against Allergan's gene targets for ophthalmic diseases.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register